Abstract
In 1995, a new cytokine termed TRAIL (tumor necrosis factor - related apoptosis-inducing ligand) was discovered and demonstrated to selectively induce programmed cell death in transformed cell lines. Preclinical cytotoxicity studies in mice and nonhuman primates have produced promising results by demonstrating that TRAIL exerts potent tumoricidal activity but lacks severe toxicity towards normal tissues making it a potentially ideal candidate for cancer therapy. This article reviews aspects of our current understanding of TRAIL signaling pathways and summarizes how this knowledge is currently being translated into TRAIL-based tumor-selective therapeutic strategies.
Current Pharmaceutical Design
Title: License to Kill Tumors: How Much Hope is Justified for Trail?
Volume: 7 Issue: 16
Author(s): S. Frank and A.D. Ebert
Affiliation:
Abstract: In 1995, a new cytokine termed TRAIL (tumor necrosis factor - related apoptosis-inducing ligand) was discovered and demonstrated to selectively induce programmed cell death in transformed cell lines. Preclinical cytotoxicity studies in mice and nonhuman primates have produced promising results by demonstrating that TRAIL exerts potent tumoricidal activity but lacks severe toxicity towards normal tissues making it a potentially ideal candidate for cancer therapy. This article reviews aspects of our current understanding of TRAIL signaling pathways and summarizes how this knowledge is currently being translated into TRAIL-based tumor-selective therapeutic strategies.
Export Options
About this article
Cite this article as:
S. Frank and A.D. Ebert , License to Kill Tumors: How Much Hope is Justified for Trail?, Current Pharmaceutical Design 2001; 7 (16) . https://dx.doi.org/10.2174/1381612013397212
DOI https://dx.doi.org/10.2174/1381612013397212 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Intraocular Immune Mechanisms in Uveitis
Current Immunology Reviews (Discontinued) Castration-resistant Prostate Cancer: The Targeting of Bone Microenvironment-related Survival Factors For Prostate Cancer Cells
Clinical Cancer Drugs Recent Developments in Particulate-Based Vaccines
Recent Patents on Drug Delivery & Formulation Proteomic Analysis of Arabidopsis Leaves Subjected to Mechanical Wounding
Current Proteomics Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials
Current Molecular Pharmacology Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine Cyclooxygenase-2 Expression, Prostacyclin Production and Endothelial Protection of High-density Lipoprotein
Cardiovascular & Hematological Disorders-Drug Targets A Review on Recent Robotic and Analytic Technologies in High Throughput Screening and Synthesis for Drug Discovery
Letters in Drug Design & Discovery Will the Real Aggrecanase(s) Step Up: Evaluating the Criteria that Define Aggrecanase Activity in Osteoarthritis
Current Pharmaceutical Biotechnology Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Anti-Inflammatory Therapeutics: Conventional Concepts and Future with Nanotechnology
Recent Advances in Inflammation & Allergy Drug Discovery Lauric Acid Modulates Cancer-Associated microRNA Expression and Inhibits the Growth of the Cancer Cell
Anti-Cancer Agents in Medicinal Chemistry High-Density Lipoprotein-Raising Strategies: Update 2010
Current Pharmaceutical Design Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Mechanisms and Consequences of Protein Aggregation: The Role of Folding Intermediates
Current Protein & Peptide Science Multi-Target Drug Design Approaches for Multifactorial Diseases: From Neurodegenerative to Cardiovascular Applications
Current Medicinal Chemistry Regulation of the Immune Response by Natural IgM: Lessons from Warm Autoimmune Hemolytic Anemia
Current Pharmaceutical Design